Valuation: Antengene Corporation Limited

Market Cap 2.46B 2.85B 363M 319M 297M 273M 511M 34.68B 520M 3.52B 1.38B 17.2B 1.36B 1.33B 59.41B P/E 2026 *
7.38x
P/E 2027 * -
Enterprise Value 2.46B 2.85B 363M 319M 297M 273M 511M 34.68B 520M 3.52B 1.38B 17.2B 1.36B 1.33B 59.41B EV / Sales 2026 *
3.47x
EV / Sales 2027 * 6.56x
Free-Float
60.27%
Yield 2026 *
-
Yield 2027 * -
1 day-4.30%
1 week-0.74%
Current month+13.60%
1 month+11.70%
3 months-21.37%
6 months+16.57%
Current year+5.80%
1 week 3.92
Extreme 3.92
4.57
1 month 3.37
Extreme 3.37
4.66
Current year 2.76
Extreme 2.76
6.28
1 year 2.76
Extreme 2.76
8.16
3 years 0.5
Extreme 0.5
8.16
5 years 0.5
Extreme 0.5
15.18
10 years 0.5
Extreme 0.5
22.5
Manager TitleAgeSince
Chief Executive Officer 60 28/08/2018
Director of Finance/CFO 44 08/06/2020
Chief Tech/Sci/R&D Officer - 20/05/2026
Director TitleAgeSince
Chairman 60 28/08/2018
Director/Board Member 51 09/11/2020
Director/Board Member 44 18/06/2021
Date Insider Type Main position Quantity % Market Cap.
02/04/26 Other

Chief Executive Officer

600,000 0.0883%
24/03/26 Other

Chief Executive Officer

100,000 0.0147%
24/03/26 Other

Chief Financial Officer

235,000 0.0346%
Change 5-day change 1-year change 3-year change Capi.($)
-4.30%-0.74%-28.65%+160.39% 363M
-0.60%+1.21%+49.22%+67.96% 55.01B
-1.32%-2.71%+34.27%+77.57% 54.24B
+1.49%+0.13%-18.03%-13.94% 23.38B
-0.57%-4.13%+2.34%+387.73% 22.57B
+2.07%+1.39%+17.20%-10.70% 20.19B
-0.52%-0.47%+29.65%-31.75% 17.86B
-2.14%-3.75%+26.23%+558.64% 15.5B
-6.69%-5.11%+169.13%+304.89% 14.2B
+1.25%+0.69%+27.30%+184.69% 14.2B
Average -1.13%-0.38%+30.87%+168.55% 23.75B
Weighted average by Cap. -0.68%-0.52%+34.78%+131.60%

Financials

2026 *2027 *
Net sales 708M 821M 105M 91.84M 85.52M 78.66M 147M 10B 150M 1.01B 397M 4.96B 393M 384M 17.13B 374M 434M 55.29M 48.53M 45.19M 41.56M 77.91M 5.28B 79.25M 536M 210M 2.62B 208M 203M 9.05B
Net income 308M 357M 45.53M 39.96M 37.21M 34.23M 64.16M 4.35B 65.26M 441M 173M 2.16B 171M 167M 7.45B -247K -286K -36.49K -32.02K -29.82K -27.43K -51.42K -3.49M -52.3K -354K -138K -1.73M -137K -134K -5.97M
Net Debt - -
Logo Antengene Corporation Limited
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Employees
129
Date Price Change Volume
29/07/26 HK$4.010 -4.30% 1,303,250
28/07/26 HK$4.190 -0.71% 1,642,500
27/07/26 HK$4.220 +3.18% 1,377,500
24/07/26 HK$4.090 +1.24% 816,500
23/07/26 HK$4.040 0.00% 618,000
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.617CNY
Average target price
4.379CNY
Spread / Average Target
+21.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 6996 Stock